We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
From May 2019 to May 2024
By Michael Dabaie
AstraZeneca PLC (AZN) said Monday an analysis of renal data from a Phase III trial showed Farxiga reduced the progression of kidney disease or renal death in patients with type 2 diabetes.
The data showed a 47% reduction with Farxiga in the relative risk of the composite renal-specific outcome of kidney function decline, end-stage renal disease, or renal death compared to placebo.
Additionally, Farxiga reduced the relative risk of a cardio-renal composite of kidney function decline, ESRD, or renal or cardiovascular death by 24% compared to placebo, AstraZeneca said.
The data are being presented at the American Diabetes Association 79th Scientific Sessions in San Francisco and simultaneously published in The Lancet Diabetes & Endocrinology.
AstraZeneca ADRs were up 0.3% premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 10, 2019 08:46 ET (12:46 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
